Pharmahungary

Executive Summary

Pharmahungary Group is a Hungarian R&D company founded in 2006, specializing in preclinical and clinical development services and in-house drug discovery for cardiovascular and metabolic diseases. The company operates as a hybrid model: providing contract research services to external partners while advancing its own pipeline of small molecule therapeutics. Leveraging over 20 years of collective scientific expertise, Pharmahungary aims to out-license its proprietary assets once they reach key preclinical proof-of-concept milestones. The company is privately held and has not disclosed total funding, but its focus on high-need areas and cost-efficient operations positions it as a potential partner for larger pharma seeking early-stage assets. Current pipeline details are not publicly available, but given its preclinical stage, upcoming value drivers include progression of lead candidates toward IND-enabling studies and securing strategic collaborations.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data for lead cardiovascular candidate50% success
• H1 2027Licensing or co-development partnership for metabolic disease program40% success
• Q3 2026Grant award from EU or Hungarian innovation fund to support R&D70% success